Lung-delivered polymer nanoparticles provoked dysfunction of the essential lung surfactant system. A steric shielding of the nanoparticle surface with poloxamers could minimize the unwanted interference of polymer nanoparticles with the biophysical function of lung surfactant. The extent of poly(styrene) and poly(lactide) nanoparticle-induced lung surfactant inhibition could be related to the type and content of the applied poloxamer. Escalations of the adsorbed coating layer thickness (>3 nm) as well as concentration (brush- rather than mushroom-like conformation of poly(ethylene glycol), chain-to-chain distance of <5 nm) on the colloidal surface were capable of circumventing bioadverse effects. Accordingly, specific formulations (i.e., poloxamer 188, 338, and 407) avoided a perturbation of the microstructure and surface activity of Alveofact and a depletion of the content of surfactant-associated proteins. Poloxamer-modified polymer nanoparticles represent a promising nanomedicine platform intended for respiratory delivery revealing negligible effects on the biophysical functionality of the lining layer present in the deep lungs.

中文翻译：

---

泊洛沙姆修饰的聚合物纳米颗粒与肺表面活性剂的相容性

肺递送的聚合物纳米颗粒引起了必需的肺表面活性剂系统的功能障碍。用泊洛沙姆对纳米颗粒表面进行空间屏蔽可以最大程度地减少聚合物纳米颗粒对肺表面活性剂的生物物理功能的有害干扰。聚（苯乙烯）和聚（丙交酯）纳米颗粒对肺表面活性剂的抑制程度可能与所用泊洛沙姆的类型和含量有关。吸附涂层厚度（> 3 nm）和浓度（刷状而不是蘑菇状）的升级胶体表面上类似的聚乙二醇构象，链间距离<5 nm）能够规避生物不利影响。因此，特定的制剂（即泊洛沙姆188、338和407）避免了Alveofact的微结构和表面活性的扰动以及与表面活性剂相关的蛋白质的含量的消耗。泊洛沙姆改性的聚合物纳米颗粒代表了一种有前途的用于呼吸道输送的纳米药物平台，对深肺中存在的衬层的生物物理功能影响微乎其微。